These findings suggest that CAP prevents hepatic steatosis by inhibiting insulin resistance-driven DNL in a TRPV1-dependent manner, thereby disrupting a central pathogenic mechanism in MASLD. Here, TRPV1 is linked to metabolic dysfunction-associated steatotic liver disease.